— Know what they know.
Not Investment Advice

AIXC NASDAQ

AIxCrypto Holdings, Inc.
1W: -28.4% 1M: +29.0% 3M: -14.4% YTD: -57.9% 1Y: -80.0% 3Y: -98.0% 5Y: -99.9%
$1.01
-0.65 (-39.16%)
 
NASDAQ · Technology · Software - Infrastructure · Tech Score Neutral · Power 55 · $20.4M mcap · 19M float · 5.81% daily turnover · Short 54% of daily vol
Smart Money Score
Watch 25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$20.4M
52W Range0.593-5.97
Volume4,886,599
Avg Volume1,078,638
Beta0.57
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOJiawei Wang
Employees10
SectorTechnology
IndustrySoftware - Infrastructure
IPO Date2015-06-23
1990 E Grand Ave
El Segundo, CA 90245
US
760 452 8111
About AIxCrypto Holdings, Inc.

AIxCrypto Holdings, Inc. is a clinical-stage biopharmaceutical company committed to discovering and developing innovative treatments for both adult and pediatric oncology. Its leading investigational therapeutic, QN-302, is a small molecule G-quadruplexes (G4)-selective transcription inhibitor currently progressing through Phase I clinical trials for pancreatic cancer and a range of other solid tumors. The firm is also advancing Pan-RAS, a preclinical-stage program targeting advanced solid tumors. Founded in 1996 and headquartered in Carlsbad, California, the company rebranded from Qualigen Therapeutics, Inc. to AIxCrypto Holdings, Inc. in November 2025.

Recent Insider Trades

NameTypeSharesPriceDate
Dodier Jason Evan 0 — 2026-08-19
Shi Chen 0 — 2026-05-21
FARADAY FUTURE INTEL 0 — 2025-11-17
FARADAY FUTURE INTEL 978,425 $2.25 2025-11-12
Wang Jiawei 0 — 2025-09-29

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms